14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
HHS vs CRESY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas CRESY carries 54.6/100 (HOLD) at $9.14 (60.1x Forward P/E, 19.3% operating margin).
Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY).
Technical & Structure Timing Caution: HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2); meanwhile CRESY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs CRESY. Trailing 12-month operating profitability (HHS -3.2% vs CRESY 19.3%) and valuation multiples (HHS 14.3x vs CRESY 60.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Conglomerates value chain with $650.9M market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment22.8% of Rev ($262M)
90D Engineering Disclosures0 Published
Investor FAQ HHS vs CRESY Key Questions & Quantitative Answers
As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas CRESY carries 54.6/100 (HOLD) at $9.14 (60.1x Forward P/E, 19.3% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY). Technical & Structure Timing Caution: HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2); meanwhile CRESY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRESY leads the Growth & Scale pillar: HHS posts -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin), compared with CRESY at +20.4% YoY revenue growth and -93.6% YoY earnings growth on $1.15B TTM revenue (42.1% gross margin, 19.3% operating margin). On trailing 12-month operating scale, HHS generates $155M in USD-normalized revenue versus $1.15B for CRESY. In operating R&D and SG&A reinvestment, HHS deploys 19.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus 22.8% of Rev ($262M) (0 disclosures) for CRESY.
HHS screens cheaper on headline valuation multiples. HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin), whereas CRESY trades at 60.1x Forward P/E, 5.9x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (20.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HHS (-30.4% ROE) versus CRESY (8.6% ROE) capital efficiency.
In options market volatility and institutional positioning, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk). By comparison, CRESY carries 74.0% implied volatility (100th %ile, Extreme (>80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.